Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
•
General Rheumatology
•
Endocrinology
•
Bone and Calcium Disorders
Would you ever consider retreatment with an antiresorptive medication in a patient with a remote history of atypical fracture attributed to an oral bisphosphonate?
(i.e. 8 years later)
Related Questions
Are there any concerns with live vaccine innoculation and patients who are on denosumab?
How do you approach a patient with elevated bone specific ALP (>2X the normal limit), but no other evidence of Paget's disease?
What is your approach to management of methotrexate osteopathy?
How do you approach significant change in BMD in premenopausal patient on tamoxifen?
Would you use romosozumab in a patient with a cardiovascular event more than 2 years prior?
Would you stop denosumab in a patient with chronic kidney disease if they develop asymptomatic hypocalcemia after the injection?
Which fracture sites outside of the classical spine and hip are considered to be osteoporotic fractures even in the absence of a bone density diagnosis?
Given the risk of hypocalcemia in dialysis dependent patients treated with denosumab, what is the best method of treatment for osteoporosis for these patients, and should we be transitioning to a different agent?
Is there any contraindication for use of Invisalign teeth aligners in patients undergoing treatment for osteoporosis?
Would you continue Forteo treatment past the recommended 2 years if T scores remain low and procollagen (P1NP) is elevated and if so, how would you monitor response?